Medios AG/€ILM1
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Medios AG
Medios AG, headquartered in Berlin, Germany, specializes in the supply and manufacturing of specialty pharmaceutical products, focusing on treatments for chronic and rare diseases. The company operates through two primary segments: Pharmaceutical Supply, offering a portfolio of approximately 1,000 specialty pharma drugs across therapeutic areas such as oncology, neurology, autoimmunology, ophthalmology, infectiology, and hemophilia; and Patient-Specific Therapies, producing individualized medications, including cytostatic infusions, antibody therapies, virostatic and antibiotic medications, and parenteral nutrition solutions, with around 400,000 preparations completed in fiscal year 2023. Founded in 2016, Medios AG has expanded its geographic footprint to include operations in Germany, the Netherlands, Belgium, and Spain. The company's strategic positioning emphasizes individualized medicine, collaborating with pharmacies, specialist practices, and pharmaceutical companies to make innovative therapies widely accessible.
Ticker
€ILM1
Sector
Primary listing
XETRA
Employees
993
Headquarters
Website
Medios AG Metrics
BasicAdvanced
€297m
21.75
€0.56
1.31
-
Price and volume
Market cap
€297m
Beta
1.31
52-week high
€17.42
52-week low
€11.74
Average daily volume
23k
Financial strength
Current ratio
1.925
Quick ratio
1.389
Long term debt to equity
33.225
Total debt to equity
33.225
Interest coverage (TTM)
2.28%
Profitability
EBITDA (TTM)
73.216
Gross margin (TTM)
9.40%
Net profit margin (TTM)
0.66%
Operating margin (TTM)
1.92%
Effective tax rate (TTM)
48.06%
Revenue per employee (TTM)
€2,140,000
Management effectiveness
Return on assets (TTM)
2.76%
Return on equity (TTM)
2.69%
Valuation
Price to earnings (TTM)
21.754
Price to revenue (TTM)
0.142
Price to book
0.57
Price to tangible book (TTM)
7.22
Price to free cash flow (TTM)
5.819
Free cash flow yield (TTM)
17.19%
Free cash flow per share (TTM)
2.081
Growth
Revenue change (TTM)
11.00%
Earnings per share change (TTM)
-5.80%
3-year revenue growth (CAGR)
8.74%
3-year earnings per share growth (CAGR)
-9.86%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
FAQs